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What, who and when? Incorporating a
discrete choice experiment into an
economic evaluation
Michela Tinelli1*, Mandy Ryan2 and Christine Bond3
Abstract
Background: Economic evaluation focuses on Quality-Adjusted-Life-Years (QALYs) as the main valuation method.
However, it is well known that factors beyond health related quality of life are important to patients and the public.
Whilst discrete-choice-experiments (DCE) have been extensively used to value such factors, their incorporation
within an economic evaluation framework is limited. This study is the first to incorporate patient preferences for
factors beyond QALYs into an economic evaluation and compare results with the standard cost-per-QALY
approach, using randomised-controlled-trial (RCT) participants.
Methods: Costings, clinical-effectiveness (appropriateness-of-treatment), QALYs and patient satisfaction data were
collected at baseline and 12-month follow-up for a new pharmacy-service within a randomised-controlled-trial. Trial
participants who replied to the follow-up survey and had not subsequently withdrawn from the study were mailed
a DCE questionnaire at 24-months. WTP for the standard and new service was derived from the DCE. Results from
QALYs and the DCE were compared.
Results: At 12 months, costs, clinical-effectiveness and QALYs did not differ between the intervention and control;
however there was a significant increase in satisfaction in the intervention. The DCE valued this increased
satisfaction in the intervention (positive net-benefit). The longer the time patients experienced the new service
the greater the reported net-benefit.
Conclusion: When incorporating a DCE into an economic evaluation a number of questions are raised: what
factors should be valued, whose values (trial-groups vs. all–trial-population) and when should they be elicited
(still-receiving-the-intervention or afterwards). Consideration should also be given to status quo bias.
Keywords: Economic evaluation, Discrete choice experiment (DCE), Willingness to pay (WTP), Quality adjusted
life year (QALY), Cost-benefit analysis (CBA), Randomised controlled trial (RCT)
Background
Economic evaluation is an integral component of health
care decision making. Whilst decision makers, such as the
UK National Institute for Health and Care Excellence
(NICE; http://www.nice.org.uk), the Scottish Medicine
Consortium (SMC; http://www.scottishmedicines.org.uk),
or the Canadian Agency for Drugs and Technologies in
Health (CADTH; https://www.cadth.ca/), make policy rec-
ommendations based on ‘health outcomes’ (e.g. clinical-
effectiveness; quality-adjusted-life-years, QALYs), the
challenge remains to find a way of incorporating a
broader measure of value, taking account of process
utility and patient experiences into economic evalua-
tions. Failure to do so may lead to incorrect policy
conclusions.
Discrete Choice Experiments (DCEs) were introduced
into health economics in the early 1990s to value aspects
of health care beyond health outcomes [1, 2]. Since then,
their use has increased to address a broad range of policy
questions. Whilst many studies have generated monetary
values from a DCE, the application of such values within
an economic evaluation is limited, with only three studies
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identified. One study [3] compared DCE generated mon-
etary values with QALYs, using different study samples.
Two other studies ([4, 5]) included a DCE within a trial,
but there was no comparable QALY data.
Despite their limited use in economic evaluations it is
acknowledged that DCEs should be considered by policy
makers and adopted as a useful tool when conducting
evaluations of health care interventions [2, 6, 7]. The
study reported here is the first, to our knowledge, to
incorporate DCEs into an economic evaluation (using a
cost benefit analysis, CBA) and compare results with the
standard cost per QALY approach (using a cost-utility
analysis, CUA), using the same trial participants. The
application is a RCT looking at extending the role of the
community pharmacist in the management of coronary
heart disease. As well as comparing the results of a CBA
and CUA analysis (what factors should be valued?
Should we go beyond QALY?), consideration is given to:
whose preferences should be elicited within a trial
(patients with different experience of the service vs.
overall sample of trial participants), and when (whilst
still receiving the intervention or afterwards)?
Methods
To address the question of what factors should be
valued the QALY and DCE approach were conducted
within the trial data using CUA and CBA respectively.
To address the question of who and when, comparison
of CUA and CBA was conducted at 3 levels:
 All trial patients (who, population with different
levels of experience of the service being valued): in
line with CUA analysis mean QALY in the
population will be estimated and considered
alongside costs, whereas for the CBA analysis, mean
WTP in the population will be estimated and
compared to costs;
 Across trial groups (who, patients with direct
experience of the service being valued:– intervention -
vs. patients with no experience of it - control): here it
is assumed that the relevant QALY and WTP
estimates come from the individuals that were part of
the intervention group (because the control group
may lack a firm understanding of the “new service”);
 Within intervention group (when, whilst still
receiving the intervention or afterwards) - here the
relevant QALY and WTP estimate are compared
between intervention subgroups either still receiving
or not receiving the Medman service at the time of
the DCE survey (intervention still receiving at
24 months and intervention not receiving at
24 months). The former group refers to patients
who continued to receive the Medman service after
trial completion on a voluntary basis.
The community pharmacy medicines management RCT
(Medman Trial)
The Medman Trial was a multicentred RCT
commissioned by the UK Department of Health to
inform changes to the community pharmacist con-
tractual framework. [8]. Subjects were male or fe-
male, aged 18 years and over, with recorded
coronary heart disease (CHD), defined as previous
myocardial infarction, angina, coronary artery by-
pass graft, or angioplasty. Patients were identified
from general practice computer systems, recruited
and randomised (2:1) to intervention (receiving the
Medman service) or control (receiving usual care).
The Medman service was a collaborative medicine
review service between the community pharmacist
and the general practitioner (GP). It included an ini-
tial consultation with a community pharmacist to re-
view: appropriateness of therapy (e.g. additional
medicine required, medicine that should be discon-
tinued, change of medicine, use of over-the-counter
(OTC) medicines, formulation issues); compliance
and concordance (e.g. daily consumption of medi-
cine, any concerns/beliefs about medicines, informa-
tion requirements); lifestyle (e.g. smoking cessation,
increased exercise and dietary change); and social
and support issues (either managing their medicines
or their condition generally). The number of subse-
quent consultations was determined by the commu-
nity pharmacist on the basis of each patient’s need,
with a maximum of four anticipated during the 12-
month follow-up. The community pharmacist com-
municated any suggested changes to prescription
medicines to the GP using a standard referral form.
The control patients received usual care from their
community pharmacists (opportunistic advice on
OTC medicines and lifestyle, and ad hoc communi-
cation with the GP) and GP (authorisation of repeat
medicines, review of medicines).
The costing exercise collected information on NHS and
patient costs, (2015 prices). More information on the cost-
ing is presented elsewhere [9]. A composite measure of
‘appropriate treatment’ was developed as a primary out-
come [8]. The primary utility measures were EuroQol
(EQ-5D; http://www.euroqol.org/) and SF-6D (http://
www.shef.ac.uk/scharr/sections/heds/mvh/sf-6d) scores.
Patient self-reported satisfaction was collected at 12 month
follow-up. A satisfaction score was developed to include
experience of and satisfaction with their most recent com-
munity pharmacy visit and was assessed by measuring
response to 15 positive and negative statements.. [10]. All
data were collected by patient completed postal surveys at
baseline and 12-month follow-up; differences between
baseline and 12-month follow-up were compared using a
paired t test.
Tinelli et al. Health Economics Review  (2016) 6:31 Page 2 of 9
Discrete choice experiment
Developing and distributing the DCE
Attributes and levels for the DCE were informed by the
aims of theMedman service, that is - to increase the chance
of receiving the most appropriate treatment; previous stud-
ies conducted in the pharmacy setting [11–13]; and analysis
of the Medman patient survey data, using Exploratory Fac-
tor Analysis (EFA) [14]. Specifically, questions describing
respondent attitudes and expectations were grouped into
summary factors: type of service provided by the pharma-
cist; the pharmacy premises; patient-pharmacist relation-
ship; a wider advisory health-related role for the
pharmacist; a traditional dispensing role for the pharmacist
[15]. A ‘cost’ (price proxy) attribute was included so that
WTP, a monetary measure of outcome, could be estimated.
The final set of attributes and levels are shown in Tables 1
and 2, more detail is provided elsewhere [15].
A labelled design was employed for the DCE using
‘Medicines review by GP & pharmacist’ (GP and PH: the
Medman service received by the intervention) and ‘Medi-
cines review by GP only’ (GP: the usual care received by
the control) labels. An orthogonal labelled 32-choice set
design was created from design catalogues using fold-
over methods [16], and subsequently allocated into four
blocks of eight choices using appropriate software [17].
A ‘current’ situation option was added to each choice set
with levels for the attributes collected in the question-
naire. Two contraction tests were included to test the
validity of responses [18]1. Responses were excluded
when individuals failed both tests; failing one test only
was considered as random error. An example of a choice
question is presented in Fig. 1.
The DCE questionnaire also collected respondent’s
socioeconomic and demographic information. Ethics
approval for the study was granted from the MREC for
Scotland as an amendment to previous approval for
conducting the Medman Trial [8].
Pilot work with 312 patients attending two general
practice clinics confirmed validity of the questionnaire
(about 90 % of respondents passed both contraction
tests) and its ability to be completed (respondents
reported a median of 3 on a 5-point Likert scale from 1
(not difficult) to 5 (very difficult)). The final DCE survey
was mailed 24 months after the baseline survey to all
trial participants who had replied to the 12-month
follow-up survey. Intervention patients were asked if
they had continued to receive the Medman service from
their pharmacist since the formal end of the Medman
Trial 12 months previously.
DCE analysis
The Hausman test showed that the IIA assumption held
across groups and the conditional logit (CL) model was
subsequently used to analyse response data, with the
following function estimated:
V ji ¼ ASCj þ β1ADVMED þ β2ADVHL
þ β3ADVMH þ β4TIME þ β5PRIVD
þ β6REPLD þ β7CH0 þ β8CH1
þ β9CH2 þ β10COST ð1Þ
Vij is the systematic part of the utility function observ-
able by the researcher of the jth choice to the ith indi-
vidual, and εji is the error term. Dummy variables were
Table 1 Medman trial data for respondents to the DCE survey
All Medman trial participants (Intervention and control combined; N = 554) P valuea
Baseline 12-month follow-up
Costs
Costs mean 1410.9 1422.895 0.85
SD 1252.87 1199.32
Difference in costs 11.995
448.22
Outcomes
Appropriate treatment score mean 4.25 4.33 0.11
SD 0.905 1.02
SF-6D Score mean 0.72 0.72 0.99
SD 0.14 0.15
EQ-5D Score mean 0.73 0.74 0.45
SD 0.24 0.265
Satisfaction score mean 42.63 46.52 <0.01
SD 9.67 16.55
aDifferences between baseline and 12-month follow-up were tested using paired t test statistics
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used to analyse categorical attributes, with reference
levels identified, and listed in Table 3, together with defi-
nitions of all labels. ASCj-1 is the Alternative Specific
Constant term, describing the general preference for
GP&PH (ASCGP&PH) or GP (ASCGP), over the ‘current’
situation (with reference level dummy variables captured
in these constants). β1-β10 are the coefficients to be
estimated.
The welfare change in moving from the control situ-
ation (‘Medicines Review by GP only)’ to the intervention
situation (‘Medicines review by GP & pharmacist)’ was
estimated2 [19] and incorporated into a CBA framework
Table 2 Medman trial data for respondents to the DCE survey (continued)




























559.12 336.23 327.00 303.40
Costs mean 1579.40 1568.20 0.90 1242.40 1277.59 0.68 1653.94 1617.20 1499.77 1515.85
SD 1323.11 1472.54 1182.63 926.10 1299.74 1510.42 1346.76 1433.45
Difference in costs −11.20 35.20 −36.73 0.77 16.08 0.89




mean 4.20 4.26 0.55 4.30 4.40 0.51 4.15 4.27 0.44 4.25 4.25 1.00
SD 0.94 1.03 0.87 1.01 0.97 0.94 0.92 1.12
SF-6D Score mean 0.71 0.71 0.55 0.73 0.73 0.66 0.70 0.69 0.14 0.72 0.73 0.28
SD 0.14 0.15 0.14 0.15 0.14 0.14 0.14 0.15
EQ-5D Score mean 0.73 0.74 0.11 0.73 0.74 0.24 0.73 0.71 0.59 0.73 0.74 0.28
SD 0.24 0.26 0.24 0.27 0.23 0.27 0.26 0.25
Satisfaction
score
mean 42.36 48.30 <0.01 42.90 44.74 0.86 45.74 52.38 0.02 39.26 43.67 <0.01
SD 9.89 15.75 9.45 17.34 9.68 15.78 9.07 14.49
aDifferences between baseline and 24-month follow-up were tested using paired t test statistics
Fig. 1 Example of DCE question
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[20, 21]. Trial costs derived at baseline and 12-month
follow-up (see Tables 1 and 2) were used. It was assumed
that there was no change in patient preferences between 12
and 24-month follow-up. Net-benefit (NB, WTP monetary
benefits – monetary costs) estimates across groups were
calculated. Differences in WTP and NB estimates were
tested across groups using appropriate tests (chi squared
test for categorical data; independent t test statistics for
continuous normally distributed data and Mann–Whitney
test statistics for continuous not normally distributed data).
The DCE data were modelled using NLOGIT 4.0, whereas
other analyses where undertaken using IBM SPSS statistics
21.0.A series of mixed logit (MXL) models were included
in the analysis to allow for unobserved heterogeneity across
individuals. Different model specifications were compared
using the log likelihood ratio index (LLRI) and the preferred
MXL (with highest LLRI) was employed to inform the
WTP estimates (see Additional file 1); its attached WTP es-
timates did not change the direction of the CBA findings
based on the CL model (see Additional file 2).
Results
The community pharmacy medicines management RCT
(Medman Trial) – a cost utility analysis
Tables 1 and 2 shows results for the subset of respon-
dents who provided 12-month follow up data and
completed the DCE (see below). No statistically signifi-
cant difference was observed across groups in costs,
appropriate treatment score or QALYs. However, satis-
faction increased for all Medman Trial patients and the
intervention patients, but not in control patients. The
DCE aimed to value this increased satisfaction.
Discrete choice experiment – a cost-benefit analysis
Patients’ responses, their characteristics and their
‘current’ situation at 24-month follow-up are shown in
Table 4. 94 % (441/469) of respondents from the inter-
vention and 96 % (235/245) of respondents from control
passed the two contraction tests. Data eligible for ana-
lysis, passing the two contraction tests and including
‘current’ situation data, came from 78 % of the respon-
dents (All Medman Trial 78, intervention 78, control 78;
intervention still receiving at 24 months 76 and interven-
tion not receiving at 24 months 79 %). The intervention
group had similar characteristics and ‘current’ experience
compared with the control group. The Intervention still
receiving at 24 months sub-group patients were signifi-
cantly older and had lower income compared with inter-
vention not receiving at 24 months (p < 0.01). Overall the
former reported more frequently that their ‘current’ situ-
ation was characterized by receiving ‘advice’ (p < 0.01),
‘privacy’ of the premises (p < 0.01), receiving ‘satisfactory
Table 3 Alternatives, attributes and levels for the DCE
Defining the alternatives Alternative Names
The Community Pharmacy Medicines Management
Project Evaluation Team (8); Tinelli et al. (13)
Medman patient survey data, analysed using Exploratory
Factor Analysis (15)
- Medicines review by GP & pharmacist (GP&PH)
- Medicines review by GP only (GP)
- ‘Current’ situation
Defining the attributes/levels Attribute name Levels and regression
coding
Ryan et al. (11); Payne et al. (12)
Medman patient survey data, analysed using Exploratory
Factor Analysis (15)
‘Advice’ [advice on medicines & health/ lifestyle] - No advice a
- Only on medicines
(ADVMED)
- Only on health/lifestyle
(ADVHL)
- On medicines & health/
lifestyle (ADVMH)
Payne et al. (12)
Medman patient survey data, analysed using Exploratory
Factor Analysis (15)
‘Privacy’ in the pharmacy [consultation with your pharmacist
is in a private area]
- No a
- Yes (PRIVD)
Tinelli et al. (13); Payne et al. (12)
Medman patient survey data, analysed using Exploratory
Factor Analysis (15)
‘Time’
[time spent travelling to, waiting in the pharmacy]
10 min; 20 min; 30 min;
40 min (TIME)
Medman patient survey data, analysed using Exploratory
Factor Analysis (15)
‘Satisfactory replies’ to your questions - No a
- Yes (REPLD)
The Community Pharmacy Medicines Management
Project Evaluation Team (8); Tinelli et al. (13)
‘Chance’ of receiving appropriate treatment - Very poor (CH0)
- Poor (CH1)
- Good (CH2)
- Very good a
Ryan et al. (11); Payne et al. (12); Tinelli et al. (13) ‘Cost’; How much you have to pay (as an indicator of value)
[cost of the medicine + the cost of the medicines review and
advice received + the cost of any travel]
£0; £10; £20; £30 (COST)
a Reference level
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replies’ (p < 0.01), shorter waiting ‘time’ (p < 0.03) or
decreased ‘costs’ (p < 0.03), and less favorable ‘chance’ of
receiving appropriate treatment (p < 0.01).
Comparison of models between groups (Table 5) showed
that at an aggregate level the ‘current’ situation was always
preferred to the alternatives of ‘Medicines review by GP &
pharmacist’ or ‘Medicines review by GP only’ (p < 0.01; all
groups). Respondents also preferred: ‘satisfactory replies’
(Compared to no reply; p < 0.01 all Medman trial, interven-
tion and its subgroups); very good ‘chance’ of receiving ap-
propriate treatment (compared with very poor/poor; p < 0.10
all groups apart from good ‘chance’ of receiving appropriate
treatment in the intervention, and poor ‘chance’ of receiving
appropriate treatment in the control)); and lower costs (p <
0.05; all groups). All Medman trial, intervention and inter-
vention still receiving groups valued receiving ‘advice’ on
medicines only (compared with no advice; p < 0.01).
WTP values are shown in Table 6 when moving from
‘Medicines review by GP only’ (usual care) to ‘GP and
Pharmacist collaboration on in Medicines review’ (Med-
man service) as follow:
 All trial patients (who, population with different
levels of experience of the state being valued): All
Table 4 DCE patient survey respondents: DCE responses, individual characteristics and ‘current’ situation at 24-month follow-up
All Medman trial
participants
Trial groups Intervention subgroups
Intervention and
control together




N (%)a N (%)a N (%)a P valueb N (%)a N (%)a P valueb
DCE completed 714 (100) 469 (100) 245 (100) - 247 (100) 222 (100) -
DCE passing
rationality tests
676 (95) 441 (94) 235 (96) - 232 (94) 208 (94) -
DCE eligible for
analysisc
554 (78) 364 (77.8) 190 (77.5) - 188 (76.1) 176 (79.3) -
Gender (male) 387 (54) 250 (69) 137 (72) 0.40 125 (66) 125 (71) 0.35
Age (mean (SD)) 70.595 (8.31) 70.44 (8.53) 70.75 (8.09) 0.67 72.00 (8.23) 68.77 (8.55) <0.01
Income 0.08 <0.01
-Up to £20,000 366 (51) 249 (79) 117 (71) 152 (87) 97 (69)
-£20,000-£40,000 100 (14) 57 (18) 43 (26) 20 (11) 37 (26)
-Over £40,000 14 (2) 9 (3) 5 (3) 2 (1) 7 (5)
‘Current’ situation
Advice 0.98 <0.01
- No advice 230 (32) 150 (41) 80 (42) 36 (19) 114 (65)
-On medicines
only
175 (25) 114 (31) 61 (32) 79 (42) 35 (20)
- On health only 9 (1) 6 (2) 3 (2) 1 (1) 5 (3)
-On Medicines/
Health/life
140 (20) 94 (26) 46 (24) 72 (38) 22 (13)
Privacy (yes) 308 (43) 215 (59) 93 (49) 0.23 146 (78) 69 (39) <0.01
Replies (yes) 267 (37) 186 (51) 81 (43) 0.06 130 (69) 56 (32) <0.01
Chance 0.34 <0.01
-Very poor 14 (2) 9 (2) 5 (3) 3 (2) 6 (3)
-Poor 204 (29) 140 (39) 64 (34) 93 (50) 47 (27)
-Good 297 (42) 190 (52) 107 (56) 88 (47) 102 (58)
-Very Good 36 (5) 23 (6) 13 (7) 3 (2) 20 (11)
Time (median
[IQR])
15 [10–30] 15 [10–30] 15 [10–30] 1 15 [10–25] 17.5 [10–30] 0.03
Cost (median
[IQR])
0 [0–0.58] 0 [0–0.58] 0 [0–0.8] 0.53 0 [0–0.4] 0 [0–0.8] 0.03
a Percentages refer to the respondents completing each question; b Differences between groups at 24-month follow-up were tested using: independent t test
statistics (continuous normally distributes data); Mann–Whitney test (continuous not normally distributed data); chi-squared test (categorical data); c Valid
responses passing rationality testing and completing answers on their ‘current’
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Medman Trial participants reported a negative
WTP value of -£26.48; this was significantly
different from both intervention and control group.
 Across trial groups (who, patients with direct
experience of the state being valued – intervention –
vs. patients with no experience of it - control): The
intervention group preferred the Medman service to
usual care (£3.52) whereas the control group did not
value the change, with a negative value (−£-56.47).
This difference was statistically significant (p < 0.01).
 Within the intervention subgroups (when, whilst still
receiving the intervention or afterwards): Those
experiencing the Medman service for 24 months
valued the service at £41.55; in comparison those
who experienced the Medman service for a
shorter period (intervention not receiving at
24 months) preferred usual care (−£34.25). This
difference was statistically significant (p < 0.01).
Prolonged experience of the Medman service,
beyond the Medman Trial, had a positive impact
on value.
Combining WTP values with costs, NB estimates
show:
 All trial patients (who, population): Negative values
for the All Medman Trial (comprising extra cost
and negative benefits). The NB for the all
Medman trial participants was negative (−£14.48)
and it was statistically significant different from
the control (−£91.67; p < 0.01) and the
intervention groups (£14.72; p < 0.01).
 Across trial groups (who, patients): The intervention
reported a reduction in costs at follow-up as well as
positive mean WTP values. It followed that a
positive NB for the Medman service was reported
(£14.72 intervention compared to -£91.67 control,
p < 0.01).
Table 5 DCE regression results
All Medman trial
participants
Trial groups Intervention subgroups
Intervention and
control together






Coeff. SE P-val Coeff. SE P-val Coeff. SE P-val Coeff. SE P-val Coeff. SE P-val
(Compared to no advice)
‘Advice’ on medicines only 0.154 .052 <0.01 0.169 0.065 <0.01 0.138 0.090 0.125 0.389 0.095 <0.01 0.126 0.100 0.204
‘Advice’ on health/lifestyle only −0.009 0.069 0.89 0.029 0.086 0.734 −0.069 0.121 0.568 0.197 0.123 0.109 −0.009 0.126 0.945
‘Advice’ on medicines & health/
lifestyle
0.019 0.055 0.721 0.074 0.068 0.276 −0.088 0.095 0.358 0.214 0.096 <0.05 0.184 0.107 0.087
(Compared to no privacy)
‘Privacy’ in the pharmacy -.016 .040 .679 0.007 0.050 0.891 −0.053 0.071 0.453 −0.010 0.071 0.893 0.126 0.074 0.090
(Compared to no reply)
‘Satisfactory replies’ to your
questions
.142 .040 <0.01 0.151 0.050 <0.01 0.134 0.071 0.058 0.197 0.068 <0.01 0.193 0.075 <0.01
(Compared to very good)
Very poor ‘chance’ of receiving
appropriate treatment
-.365 .069 <0.01 −0.371 0.086 <0.01 −0.360 0.121 <0.01 −0.466 0.121 <0.01 −0.262 0.125 <0.05
Poor ‘chance’ of receiving
appropriate treatment
-.222 .063 <0.01 −0.255 0.078 <0.01 −0.163 0.109 0.134 −0.244 0.111 <0.05 −0.209 0.114 0.066
Good ‘chance’ of receiving
appropriate treatment
-.155 .059 <0.01 −0.083 0.073 0.255 −0.312 0.106 <0.01 −0.083 0.106 0.433 −0.055 0.104 0.595
TIME -.003 .002 .116 −0.003 0.002 0.101 −0.002 0.003 0.600 −0.001 0.003 0.646 −0.007 0.003 <0.05
COST -.008 .002 <0.01 −0.009 0.003 <0.01 −0.007 0.004 0.080 −0.010 0.004 0.013 −0.009 0.004 <0.05
(compared to current)
Medicines review by GP &
Pharmacista
−1.128 .059 <0.01 −0.990 0.071 <0.01 −1.420 0.108 <0.01 −0.640 0.101 <0.01 −1.443 0.110 <0.01
Medicines review by GP onlya -.994 .057 <0.01 −0.997 0.070 <0.01 −1.013 0.101 <0.01 −0.943 0.105 <0.01 −1.057 0.103 <0.01
No of observations 4445 2916 1529 1501 1415
No of individuals 554 364 190 188 176
aEverything else constant
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 Within the intervention subgroups (when):
Prolonged experience of the Medman service,
beyond the Medman Trial, had a positive impact on
NB estimates (£78.29 intervention still receiving at
24 months compared to -£50.33 intervention not
receiving at 24 months, p < 0.01).
Discussion
The results provide evidence that the DCE approach is
able to value increased satisfaction. This is consistent with
the extensive health economics literature suggesting
values from the process utility benefits, using discrete
choice experiments and contingent valuation [1, 2, 22, 23].
This findings also raises the question of whose
values should be elicited in an economic evaluation,
and when.
Whose values should be elicited in an economic evalu-
ation? Our study elicited patient values, assuming
patients themselves should be asked to value their own
health state given that they have direct experience of the
state being valued, and compared results from all trial
population and trial groups with different experience of
the service. It could be argued that the relevant QALY
and WTP estimates should come from the individuals
that were part of the intervention group because the
control group may lack a firm understanding of the new
Medman service.
This paper goes further, arguing that patient values
beyond health outcomes should be incorporated into an
economic evaluation (what factors should be valued?
Should we go beyond QALY?). Internationally, policy
makers have recognised the importance of considering pa-
tients’ experiences. For example, the World-Health-
Organization (WHO; http://www.who.int) considers that
service ‘responsiveness’ describes how a healthcare system
meets people’s needs, the Institute-of-Medicine (IOM;
http://www.nationalacademies.org/) identifies ‘patient cen-
tered care’ as a key dimension of healthcare quality, and
many national governments and healthcare organisations
include these or similar concepts in their decision making
(e.g. see NHS confederation covering NHS policy develop-
ments in UK and Europe, http://www.nhsconfed.org).
When should values be elicited? When considering the
standard CBA approach comparing intervention and
control groups the negative net benefit does not support
the introduction of the intervention (extending the role
of the pharmacist); however if we focus on the interven-
tion group, results are supportive, but only for those still
receiving the intervention at 24 months. This is not sur-
prising as these individuals preferred the Medman ser-
vice and decided to continue beyond 12-month trial
follow-up (pending on the availability of the community
pharmacist and the GP joint agreement to continue its
delivery). It may be argued that the analysis within the
intervention group may not be informative for the pur-
pose of the economic evaluation and findings from the
standard CBA approach comparing trial intervention
and control should be preferred to inform policy.
The WTP suggested status quo bias [1], with those
still receiving the intervention at 24 months preferring it
compared to those who had not experienced it. Further,
length of time experiencing the intervention had a sig-
nificant positive effect on WTP, perhaps providing more
evidence of status quo bias. People tend to follow the
status quo when making health-related decisions and
they most value the service they experience.
To our knowledge this is the first study to incorporate
DCE WTP estimates into an economic evaluation and
compare results with a CUA (clinical-effectiveness and
QALYs). A limitation is that the comparison was not
contemporaneous, and there is no data on the clinical
and QALY measures at the 24 month point. Nonetheless
the study adds to the limited CBA applications available
within the health care literature, and informs current
discussion on whether the choice of evaluation approach
can impact on adopting decisions. It also raises issues
that are important in this future and important research
agenda.
Table 6 WTP estimates (£) at 24-month follow-up and Net Benefit analysis
















Willingness to pay (WTP)
when moving from ‘Medicines
review by GP only’ to ‘Medicines
review by GP & Pharmacist’
mean −26.475 <0.01 <0.01 3.52 −56.47 <0.01 41.55 −34.25 <0.01
SD 10 1.17 18.83 13.85 11.42
Difference in societal costs from
Tables 1 and 2
11.99 −11.20 +35.20 −36.73 +16.08
Net Benefit (NB)b mean −38.47 0.44 0.30 14.72 −91.67 <0.01 78.29 −50.33 <0.01
SD 229.11 1620.60 1167.68 1706.09 1528.41
a Differences between groups at 24-month follow-up were tested using Mann–Whitney test statistics. b NB was calculated as: (WTP at 24-month follow-up, from
DCE patient survey data; see Table 5) – (difference in society costs, from Medman Trial data see Tables 1 and 2)
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Conclusion
Policy decision making requires consideration of pa-
tient preferences and, moreover, the information on
preferences can be used to develop effective delivery
of community pharmacy service. However, findings
from this study suggest when incorporating a discrete
choice experiment into a trial economic evaluation,
important issues that need to be addressed include:
what factors should be valued, whose values (and
when) should be elicited, and status quo bias.
Endnotes
1The rationality tests applied Sen’s contraction test.
Here, individuals were initially presented with a choice
set involving three choices (“Medicines review by GP&
pharmacist”, “Medicines review by GP only” and “Your
‘current’ situation”). This choice was then repeated later
in the questionnaire, with the choice set contracted to
two options (“Medicines review by GP only”, and “Your
‘current’ situation”). These two options depended on
what they chose initially, with the option they chose and
one of the other options from the original three choices
being presented. The individual should choose the same
option when the choice set is contracted.
2A state of the world model was assumed.
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